Free tool
FAERS Monitor: Syprine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019194 or its brand name (Syprine, Trientine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
184
Serious
106
58% of reports
Hospitalization
50
Death reported
18
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug dose omission19
- therapy interrupted17
- product storage error13
- drug ineffective11
- insurance issue11
- treatment noncompliance11
- condition aggravated10
- nausea10
- enteritis9
- hepato-lenticular degeneration9
- no adverse event9
- death8
- fatigue8
- hospitalisation8
- memory impairment8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 6 |
| 2007 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 14 |
| 2017 | 41 |
| 2018 | 20 |
| 2019 | 12 |
| 2020 | 17 |
| 2021 | 20 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 9 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,975 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepato-lenticular degenerationSignal | 9 | 8801.8 | 4538.2 | 65,597 |
| enteritisSignal | 9 | 161.0 | 85.1 | 1,274 |
| insurance issueSignal | 11 | 82.3 | 46.4 | 804 |
| therapy interruptedSignal | 17 | 27.2 | 17.3 | 404 |
| treatment noncomplianceSignal | 11 | 23.0 | 13.0 | 210 |
| product storage errorSignal | 13 | 17.0 | 10.1 | 181 |
| drug dose omissionSignal | 19 | 13.1 | 8.6 | 203 |
| memory impairmentSignal | 8 | 6.7 | 3.4 | 33 |
| hospitalisationSignal | 8 | 6.0 | 3.0 | 28 |
| no adverse eventSignal | 9 | 5.7 | 3.0 | 30 |
| condition aggravatedSignal | 10 | 3.8 | 2.1 | 18 |
| nausea | 10 | 1.4 | 0.8 | 1 |
| fatigue | 8 | 1.2 | 0.6 | 0 |
| death | 8 | 1.1 | 0.5 | 0 |
| drug ineffective | 11 | 1.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.